3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasms
5
Stomach Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Vomiting
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Nodule
1
Thyroid Neoplasms
1
Thromboembolism
1
Thrombocytopenia
1
Stomatitis
1
Spondylitis, Ankylosing
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Scleroderma, Localized
1
Psoriasis
1
Postoperative Hemorrhage
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Pancreatic Cyst
1
Pain, Postoperative
1
Pain
1
Interventions
Bupivacaine
4
Morphine
2
Diazepam
2
Botulinum Toxins, Type A
2
oxycodone-acetaminophen
1
Sodium Chloride
1
Saline Solution
1
Ropivacaine
1
Neck Dissection
1
Narcotics
1
Ketamine
1
Hypnotics and Sedatives
1
Gabapentin
1
Epinephrine
1
Dexamethasone
1
Calcium Dobesilate
1
Botulinum Toxins
1
Analgesics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pain, Postoperative
×
Saline Solution
×
Clear all
NCT00210210
2025-09-19
KETAMINE
Institut Bergonié
Phase 3
Completed
230 enrolled
6 charts